Patents by Inventor Sarah BETHUNE

Sarah BETHUNE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRYSTAL FORMS OF 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL]PIPERAZIN-1-YL]ETHYL PYRIDINE-3-CARBOXYLATE
    Publication number: 20230331677
    Abstract: The invention provides polymorphs of a compound of Formula (X): The invention also provided pharmaceutical compositions containing polymorphs of the compound and methods treating conditions in a subject by providing polymorphs of the compound.
    Type: Application
    Filed: June 21, 2023
    Publication date: October 19, 2023
    Inventors: Neil Buckley, Dan Belmont, Sarah Bethune, Krista Diaz
  • Crystal forms of 2-[4-[(2,3,4- trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
    Patent number: 11746090
    Abstract: The invention provides polymorphs of a compound of Formula (X): The invention also provided pharmaceutical compositions containing polymorphs of the compound and methods treating conditions in a subject by providing polymorphs of the compound.
    Type: Grant
    Filed: November 14, 2022
    Date of Patent: September 5, 2023
    Assignee: IMBRIA PHARMACEUTICALS, INC.
    Inventors: Neil Buckley, Dan Belmont, Sarah Bethune, Krista Diaz
  • CRYSTAL FORMS OF 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL]PIPERAZIN-1-YL]ETHYL PYRIDINE-3-CARBOXYLATE
    Publication number: 20230093615
    Abstract: The invention provides polymorphs of a compound of Formula (X): The invention also provided pharmaceutical compositions containing polymorphs of the compound and methods treating conditions in a subject by providing polymorphs of the compound.
    Type: Application
    Filed: November 14, 2022
    Publication date: March 23, 2023
    Applicant: IMBRIA PHARMACEUTICALS, INC.
    Inventors: Neil Buckley, Dan Belmont, Sarah Bethune, Krista Diaz
  • Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
    Patent number: 11530184
    Abstract: The invention provides polymorphs of a compound of Formula (X): The invention also provided pharmaceutical compositions containing polymorphs of the compound and methods treating conditions in a subject by providing polymorphs of the compound.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: December 20, 2022
    Assignee: IMBRIA PHARMACEUTICALS, INC.
    Inventors: Neil Buckley, Dan Belmont, Sarah Bethune, Krista Diaz
  • CRYSTAL FORMS OF 2-[4-[(2,3,4-TRIMETHOXPHENYL)METHYL]PIPERAZIN-1-YL]ETHYL PYRIDINE-3-CARBOXYLATE
    Publication number: 20210403428
    Abstract: The invention provides polymorphs of a compound of Formula (X): The invention also provided pharmaceutical compositions containing polymorphs of the compound and methods treating conditions in a subject by providing polymorphs of the compound.
    Type: Application
    Filed: June 28, 2021
    Publication date: December 30, 2021
    Inventors: Neil Buckley, Dan Belmont, Sarah Bethune, Krista Diaz
  • Cocrystal forms of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl) methyl sulfamate, formulations and uses thereof
    Patent number: 11124519
    Abstract: The present invention is directed to cocrystal forms of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxcyclopentyl) methyl sulfamate of formula (I). The invention is also directed to methods of making cocrystal forms of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl) methyl sulfamate of formula (I). The invention is also directed to the pharmaceutical use of a cocrystal form as an E1 activating enzyme inhibitor, as well as a pharmaceutical composition comprising a cocrystal form. The invention is further directed to a method of treatment comprising administering a cocrystal form of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate of formula (I).
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: September 21, 2021
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Patricia Andres, Sarah Bethune, Marianne Langston, Debra L. Mazaik
  • CRYSTAL FORMS OF AN ALK2 INHIBITOR
    Publication number: 20210238185
    Abstract: The invention relates to crystalline forms of an ALK2 inhibitor, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to pharmaceutical uses of the crystalline forms.
    Type: Application
    Filed: April 23, 2021
    Publication date: August 5, 2021
    Inventors: Sarah BETHUNE, Krista DIAZ, Catherine A. EVANS
  • COCRYSTAL FORMS OF ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO [2,3-D]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL) METHYL SULFAMATE, FORMULATIONS AND USES THEREOF
    Publication number: 20200277294
    Abstract: The present invention is directed to cocrystal forms of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxcyclopentyl) methyl sulfamate of formula (I). The invention is also directed to methods of making cocrystal forms of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl) methyl sulfamate of formula (I). The invention is also directed to the pharmaceutical use of a cocrystal form as an E1 activating enzyme inhibitor, as well as a pharmaceutical composition comprising a cocrystal form. The invention is further directed to a method of treatment comprising administering a cocrystal form of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate of formula (I).
    Type: Application
    Filed: September 20, 2018
    Publication date: September 3, 2020
    Inventors: Patricia ANDRES, Sarah BETHUNE, Marianne LANGSTON, Debra L. MAZAIK